SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A decent increase of about 49.94% in the sales to Rs. 25.55 millions was observed for the quarter ended December 2024. The sales figure stood at Rs. 17.04 millions during the year-ago period.The Net Loss for the quarter ended December 2024 is Rs. -13.23 millions as compared to Net Loss of Rs. -16.28 millions of corresponding quarter ended December 2023 Operating profit Margin for the quarter ended December 2024 improved to -13.95% as compared to -17.20% of corresponding quarter ended December 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 25.55 17.04 49.94 68.45 71.55 -4.33 102.88 10.04 924.70
Other Income 1.22 0.24 408.33 2.00 2.36 -15.25 3.33 3.99 -16.54
PBIDT -13.95 -17.20 -18.90 -29.18 -35.98 -18.90 -32.39 -40.45 -19.93
Interest 2.23 2.97 -24.92 7.58 9.42 -19.53 12.20 12.14 0.49
PBDT -16.18 -20.17 -19.78 -36.76 -45.40 -19.03 -44.59 -52.59 -15.21
Depreciation 1.87 1.83 2.19 5.53 5.38 2.79 7.20 6.18 16.50
PBT -18.05 -22.00 -17.95 -42.29 -50.78 -16.72 -51.79 -58.77 -11.88
TAX -4.82 -5.72 -15.73 -10.74 -4.77 125.16 -6.65 -2.15 209.30
Deferred Tax -4.82 -5.72 -15.73 -10.74 -4.77 125.16 -6.65 8.38 -179.36
PAT -13.23 -16.28 -18.73 -31.55 -46.01 -31.43 -45.14 -56.62 -20.28
Equity 123.10 93.80 31.24 123.10 93.80 31.24 94.33 75.11 25.59
PBIDTM(%) -54.60 -100.94 -45.91 -42.63 -50.29 -15.23 -31.48 -402.89 -92.19

Vista Pharma Share Price

8.05 0.86 (11.96%)
22-Apr-2026 10:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1660.25
Dr. Reddys Lab 1214.95
Cipla 1227.85
Zydus Lifesciences 928.65
Lupin 2297.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×